Dyslipidemia - Drug Pipeline Analysis and Market Forecasts to 2016

The Dyslipidemia Market is Forecast to Decline until 2016

Online PR News – 26-February-2010 – – GlobalData estimated the global dyslipidemia market to be valued at $34.4 billion in 2009. It is expected to decline at a compound annual growth rate (CAGR) of approximately 3.7% from $34.4 billion in 2009 to $26.3 billion by 2016. Although the cardiovascular market expanded considerably from 2004 to 2008, growth in the seven major markets is expected to slow down from 2013 onwards. The decline in sales during this period will be due to the expiry of many leading brands’ patents. Pfizer’s Lipitor, a major blockbuster in the dyslipidemia market, is set to expire in 2011. Following the expiry of Lipitor’s patent, Simcor and Trilipix’s patents will also expire in 2011. The patents of Zetia, Vyotrin, Lescol, Livalo and Lovaza are set to expire between 2012 and 2014. The market growth will be sustained by the launch of major new products with safety and convenience advantages such as once-daily administration and combinational therapies. The New Drug Application for Cetriad, being co-developed by AstraZeneca and Abbott Laboratories, has been filed with the US FDA and is currently the most anticipated drug in the pipeline.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Dyslipidemia-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Healthcare

GlobalData found that the current competition in the dyslipidemia market is becoming intense due to the increased entry of combinational therapies and the use of statins, fibrates, niacin and omega-3 fatty acid derivatives as antidyslipidemic agents. It projects that Lipitor, Trilipix and Simcor will be the leading competitiors in the global dyslipidemia market. Pfizer, Abbott Laboratories, AstraZeneca and Merck will continue to be the market leaders until the patents on their drugs expire inbetween 2011 and 2014. The market is set to shrink following the expiry of Pfizer’s Lipitor. Also Simcor, Trilipix, Vyotrin, Zetia, Lescol, Lovaza and Livalo are all set to expire between 2011 and 2014. The dyslipidemia market is expected to show decline due to patent expiries in the near future.

GlobalData found that there are over 98 molecules in various stages of the pipeline. Cetriad, Trilipix in combination with atorvastatin, Trilipix in combination with simvastatin, RG1658, MK-0524A, Caduet, GFT-505, AEGR-733, AMR-101and MK-859 are some of the promising molecules in the late stage pipeline of dyslipidemia. Some of these molecules differ in their target and mechanism of action from the existing therapies. Most of these molecules are combination products of already marketed drugs. Novelty exists in terms of using two different drugs in combination in order to increase efficacy. Some of the drugs in the late stage pipeline, such as GFT-505 and MK-0524A, are completely novel to the dyslipidemia market and these drugs, if approved, would introduce drug classes with better efficacy. Although the dyslipidemia pipeline is strong in terms of first-in-class and me-too products, only a small number of products are expected to enter the market before 2016. Inspite of the strong pipeline, the market is declining due to the patent expiries of major blockbuster drugs.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Dyslipidemia-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Healthcare

GlobalData, the industry analysis specialist’s new report, “Dyslipidemia - Drug Pipeline Analysis and Market Forecasts to 2016" is an essential source of information and analysis on the global dyslipidemia market. The report identifies the key trends shaping and driving the global dyslipidemia market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global dyslipidemia sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

Visit our report store: http://www.globaldata.com/reportstore

Bookmarkse-mailGoogledel.icio.usStumbleUponSlashdotFurlDiggTechnoratiYahooMyWebBlinkListSpurlRawSugarWists
 
 
Contact Information
Rajesh Gunnam
Progressive House, Maidstone Road, Foots Cray, Sidcup
Kent London, DA14 5HZ

+914066166782